Deals

MSN Laboratories has struck a patent-litigation settlement deal with BeiGene that will allow it to launch its zanubrutinib generic rival to Brukinsa in the US from 2037.

Having previously set itself a deadline of the end of November to strike a licensing deal for one of two biosimilar candidates – or risk failing to meet its working capital requirements – Sweden’s Xbrane has now announced a global licensing partnership with Intas for its nivolumab Opdivo rival, with just days to spare.

Ten $1bn+ alliances were penned in October, and three exceeded $2bn.

The German group is doubling down on the hot PD-(L)1 x VEGF-A bispecific space but will still have to contend with Summit and Akeso’s more advanced rival.

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

Fresenius Kabi-controlled mAbxience has struck a deal with Servier’s Egis Pharmaceutical to commercialize two biosimilar candidates in multiple central and eastern European markets.

Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.

Meitheal has announced a licensing agreement with parent company Hong Kong King-Friend to add another three biosimilars to its pipeline for the US market.

Two more generics manufacturers have settled claims with 50 US attorneys general that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.

The Denmark-based major intends to build on its heritage in diabetes and is keen to hear from innovators in a space where prevalence is on the rise but is not being served by improved new products.